The effect of orlistat treatment on cardiovascular novel inflammatory biomarkers

Increase in prevalence of obesity has become a worldwide major health problem. In general, greater body mass index (BMI) is associated with increased rate of death. New inflammatory markers (such as monocyte-to-HDL ratio (MHR), and cardiac risk ratio (CRR)) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine. Although they have been tested in many different diseases and conditions, how they have been affected in patients receiving orlistat therapy due to obesity has never been evaluated before. In this retrospective study, 197 patients who received orlistat treatment for the first time were included in the study were enrolled. All data (such as demographic profile, lipid profile, hs-CRP, hemogram, and biochemical parameters) of patients before the treatment and at the 3rd-month control after orlistat treatment were recorded. The gender ratios of the patients were male (%46.7) and female (%53.3) and mean age of patients was 47.13±10.9 years. In the comparison of patients before and after treatment, BMI was significantly decreased and the mean change was 3.4054 (p

PDF

___

1. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1–17.

2. Obesity and overweight [Internet]. 16 February 2018. Available from: https:// www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight

3. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA. 2006;296:79–86.

4. Afshin A, Forouzanfar MH, Reitsma MB, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377:13–27.

5. Saunders KH, Umashanker D, Igel LI, et al. Obesity Pharmacotherapy. Med Clin North Am. 2018;102:135–48.

6. Bolayir A, Bolayir E. Can lymphocyte to monocyte ratio be used as a predictor of atherosclerotic carotid plaques in elderly adults? Cumhur Tıp Derg. 2017;40:120–7.

7. Cetin EHO, Cetin MS, Canpolat U, et al. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark Med. 2015;9:967–77.

8. Dobiasova M. AIP, Atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006;52:64–71.

9. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102:653–7.

10. E. Turan, “Evaluation of neutrophil-to-lymphocyte ratio and hematologic parameters in patients with Graves’ disease.,” Bratisl. Lek. Listy, vol. 120, no. 6, pp. 476–80, 2019.

11. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):102-38.

12. Bray GA, Fruhbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet (London, England). 2016;387:1947–56.

13. Vallis M. Quality of life and psychological well-being in obesity management: improving the odds of success by managing distress. Int J Clin Pract. 2016;70:196–205.

14. Wilding J. Orlistat: should we worry about liver inflammation? Vol. 346, BMJ (Clinical research ed.). England; 2013. p. f2777.

15. Yesilbursa D, Serdar A, Heper Y, et al. The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol. 2005;60:265–9.

16. Hsieh C-J, Wang P-W, Liu R-T, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract. 2005;67:78–83.

17. Marginean CO, Melit LE, Ghiga DV, et al. Early Inflammatory Status Related to Pediatric Obesity. Front Pediatr. 2019;7:241.

18. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640–9.

19. Chan JC, Cheung JC, Stehouwer CD, et al. The central roles of obesityassociated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome – an analysis by structural equation modelling. Int J Obes Relat Metab Disord. 2002;26:994–1008.

20. Madsen EL, Rissanen A, Bruun JM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol. 2008;158:179–87.

21. Esposito K, Pontillo A, Di Palo C, et al. Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese WomenA Randomized Trial. JAMA . 2003;289:1799–804.

22. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab. 2003;5:195–201.

23. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. HORMONES-ATHENS-. 2006;5:259.

24. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–9.

25. Al-Tahami BAM, Al-Safi Ismail AA, Sanip Z, et al. Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects. J Nippon Med Sch. 2017;84:125–32.

26. Derosa G, Maffioli P, Ferrari I, et al. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol [Internet]. 2011;25:642–51.

27. Osadnik T, Bujak K, Osadnik K, et al. Novel inflammatory biomarkers may reflect subclinical inflammation in young healthy adults with obesity. Endokrynol Pol. 2019;70:135–42.

28. Osadnik T, Wasilewski J, Lekston A, Strzelczyk J, Kurek A, Gonera M, et al. The platelet-to-lymphocyte ratio as a predictor of all-cause mortality in patients with coronary artery disease undergoing elective percutaneous coronary intervention and stent implantation. J Saudi Hear Assoc. 2015;27:144–51.

29. Wasilewski J, Pyka L, Hawranek M, et al. Prognostic value of neutrophiltolymphocyte ratio in predicting long-term mortality in patients with ischemic and nonischemic heart failure. Pol Arch Med Wewn. 2016;126:166–73.

30. Jia S-J, Gao K-Q, Zhao M. Epigenetic regulation in monocyte/macrophage: A key player during atherosclerosis. Cardiovasc Ther. 2017;35.

31. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein AI and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Que´ bec Cardiovascular Study. Circulation. 1996;94:273–8.

32. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the quebec cardiovascular study. Arch Intern Med. 2001;161:2685–92.